NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel

British Journal of Cancer

Volumn 95, Issue 5, 2006, Pages 601-606

  Negishi, T ^a   Koizumi, F ^a   Uchino, H ^b   Kuroda, J ^a   Kawaguchi, T ^c   Naito, S ^b   Matsumura, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Drug delivery system; NK105; Paclitaxel; Polymer micelle; Radiosensitiser

Indexed keywords

NANOPARTICLE; NK 105; PACLITAXEL; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CHRONOTHERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; DRUG SYNTHESIS; EXCISION; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; INTERMETHOD COMPARISON; LEWIS CARCINOMA; LUNG; LUNG FIBROSIS; LUNG TOXICITY; MEDICAL ASSESSMENT; MICELLE; MOUSE; MULTIMODALITY CANCER THERAPY; NONHUMAN; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INJURY; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; COLLAGEN TYPE III; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; LUNG; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; PACLITAXEL; RADIATION-SENSITIZING AGENTS; RATS; RATS, INBRED LEW;

EID: 33748289523     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603311     Document Type: Article

References (45)

1. Allen TM (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15: 215-220
2. Arriagada R, Le Chevalier T, Quoix E, Ruffie P, de Cremoux H, Douillard JY, Tarayre M, Pignon JP, Laplanche A (1991) ASTRO (American Society for Therapeutic Radiology and Oncology) plenary: Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Etude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 20: 1183-1190
3. Ashcroft T, Simpson JM, Timbrell V (1988) Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 41: 467-470
4. Carney DN (1996) Chemotherapy in the management of patients with inoperable non-small cell lung cancer. Semin Oncol 23: 71-75
5. Chen Y, Okunieff P (2004) Radiation and third-generation chemotherapy. Hematol Oncol Clin North Am 18: 55-80
6. Chen Y, Pandya K, Keng PC, Johnstone D, Li J, Lee YJ, Smudzin T, Okunieff P (2003) Phase I/II clinical study of pulsed paclitaxel radiosensitization for thoracic malignancy: a therapeutic approach on the basis of preclinical research of human cancer cell lines. Clin Cancer Res 9: 969-975
7. Choy H, Akerley W, Safran H, Graziano S, Chung C, Williams T, Cole B, Kennedy T (1998a) Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 16: 3316-3322
8. Choy H, Devore III RF, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47: 931-937
9. Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD (1993) Investigation of taxol as a potential radiation sensitizer. Cancer 71: 3774-3778
10. Choy H, Safran H, Akerley W, Graziano SL, Bogart JA, Cole BF (1998b) Phase II trial of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Clin Cancer Res 4: 1931-1936
11. Cividalli A, Arcangeli G, Cruciani G, Livdi E, Cordelli E, Danesi DT (1998) Enhancement of radiation response by paclitaxel in mice according to different treatment schedules. Int J Radiat Oncol Biol Phys 40: 1163-1170
12. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry MC, Carey RW, Frei III EF, Green MR (1990) A randomized trial of induction chemotherapy plus high-dose radiation vs radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323: 940-945
13. Dowell JE, Sinard R, Yardley DA, Aviles V, Machtay M, Weber RS, Weinstein GS, Chalian AA, Carbone DP, Rosenthal DI (1999) Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers. Semin Radiat Oncol 9: 97-101
14. Early Breast Cancer Trialists' Collaborative Group (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 355: 1757-1770
15. Ellerbroek N, Martino S, Mautner B, Tao ML, Rose C, Botnick L (2003) Breast-conserving therapy with adjuvant paclitaxel and radiation therapy: feasibility of concurrent treatment. Breast J 9: 74-78
16. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, Press M, Danenberg P, Muggia F (2003) Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21: 864-870
17. Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y (1999) Phase III study of concurrent vs sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 17: 2692-2699
18. Gabizon A, Chemla M, Tzemach D, Horowitz AT, Goren D (1996) Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines. J Drug Target 3: 391-398
19. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92: 1240-1246
20. Hanna YM, Baglan KL, Stromberg JS, Vicini FA, A Decker D (2002) Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 8: 149-153
21. Kao J, Conzen SD, Jaskowiak NT, Song DH, Recant W, Singh R, Masters GA, Fleming GF, Heimann R (2005) Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys 61: 1045-1053
22. Khayat D, Antoine EC, Coeffic D (2000) Taxol in the management of cancers of the breast and the ovary. Cancer Invest 18: 242-260
23. Klibanov AL, Maruyama K, Beckerleg AM, Torchilin VP, Huang L (1991) Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. Biochim Biophys Acta 1062: 142-148
24. Klibanov AL, Maruyama K, Torchilin VP, Huang L (1990) Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett 268: 235-237
25. Lind PA, Marks LB, Hardenbergh PH, Clough R, Fan M, Hollis D, Hernando ML, Lucas D, Piepgrass A, Prosnitz LR (2002) Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 52: 137-143
26. Lokeshwar BL, Ferrell SM, Block NL (1995) Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy. Anticancer Res 15: 93-98
27. Maeda H, Matsumura Y (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug Carrier Syst 6: 193-210
28. Mason KA, Milas L, Peters LJ (1995) Effect of paclitaxel (taxol) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys 32: 1381-1389
29. Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46: 6387-6392
30. Milas L, Hunter NR, Mason KA, Kurdoglu B, Peters LJ (1994) Enhancement of tumour radioresponse of a murine mammary carcinoma by paclitaxel. Cancer Res 54: 3506-3510
31. Milas L, Hunter NR, Mason KA, Milross CG, Saito Y, Peters LJ (1995) Role of reoxygenation in induction of enhancement of tumour radioresponse by paclitaxel. Cancer Res 55: 3564-3568
32. Morton RF, Jett JR, McGinnis WL, Earle JD, Therneau TM, Krook JE, Elliott TE, Mailliard JA, Nelimark RA, Maksymiuk AW (1991) Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A randomized, phase III trial. Ann Intern Med 115: 681-686
33. Penney DP, Rubin P (1977) Specific early fine structural changes in the lung irradiation. Int J Radiat Oncol Biol Phys 2: 1123-1132
34. Rodriguez M, Sevin BU, Perras J, Nguyen HN, Pham C, Steren AJ, Koechli OR, Averette HE (1995) Paclitaxel: a radiation sensitizer of human cervical cancer cells. Gynecol Oncol 57: 165-169
35. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11: 2010-2020
36. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332: 1004-1014
37. Sause W, Kolesar P, Taylor SI, Johnson D, Livingston R, Komaki R, Emami B, Curran Jr W, Byhardt R, Dar AR, Turrisi III A (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 117: 358-364
38. Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29: 450-474
39. Taghian AG, Assaad SI, Niemierko A, Kuter I, Younger J, Schoenthaler R, Roche M, Powell SN (2001) Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 93: 1806-1811
40. Terasima T, Tolmach LJ (1963) X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 140: 490-492
41. Tishler RB, Geard CR, Hall EJ, Schiff PB (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497
42. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T (2005) Cisplatinin-corporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer 93: 678-687
43. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker Jr JR, Van Echo DA, Von Hoff DD, Leyland-Jones B (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8: 1263-1268
44. Yu TK, Whitman GJ, Thames HD, Strom E, McNeese MD, Perkins GH, Schechter N, Kau S, Buzdar AU, Hortobagyi GN, Thomas E, Buchholz TA (2003) Clinically-relevant pneumonitis is not increased in breast cancer patients treated with sequential paclitaxel and radiation. Int J Radiat Oncol Biol Phys 57(2 Suppl): S127-S128
45. Yu TK, Whitman GJ, Thames HD, Buzdar AU, Strom EA, Perkins GH, Schechter NR, McNeese MD, Kau SW, Thomas ES, Hortobagyi GN, Buchholz TA (2004) Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 96: 1676-1681